Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,501 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01147562 | Biomarker Discovery and Validation in Lung Cancer(LCS) | unknown | N/A | 150 | Dr. Guy BerchemOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 |
| NCT03823807 | A Study to Evaluate the Safety and Efficacy of SH-1028 in Locally Advanced or Metastatic NSCLC | unknown | Phase 2 | 300 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Feb 1, 2019 | clinicaltrials |
| NCT03397355 | Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy. | unknown | — | 1,000 | China-Japan Friendship HospitalOTHER | 1 | Jan 31, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03162705 | Molecular Profiling in Small Cell Lung Cancer(MPSCLC) | unknown | — | 120 | Zhujiang HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03802409 | The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment | unknown | — | 500 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03811054 | The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 60 | Beijing Chest HospitalOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT03029273 | NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC | unknown | Phase 1 | 20 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT02480634 | Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer | unknown | Phase 4 | 280 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 0 | Jan 16, 2019 | clinicaltrials |
| NCT03804307 | Short Course Radiation Therapy in Palliative Treatment of Thoracic Cancer | unknown | N/A | 72 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03802266 | Electromagnetic Navigation Versus CT Guided TTNA in the Diagnosis of Early Peripheral Lung Cancer | unknown | N/A | 322 | Shanghai Chest HospitalOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03799601 | Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC(ALTER-L013) | unknown | Phase 4 | 45 | Tongji HospitalOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03791151 | Pharmacogenetics in Non Small Cell Lung Cancer | unknown | — | 100 | Ain Shams UniversityOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT03565120 | Aggressive Thoracic Radiotherapy for Stage Ⅳ Non Small Cell Lung Cancer | unknown | N/A | 60 | yu gengshengOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT03780283 | Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | unknown | Phase 2 | 30 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02804893 | Videothoracoscopic (VATS) vs. Robotic Approach for Lobectomy or Anatomical Segmentectomy(ROMAN) | unknown | N/A | 300 | Istituto Clinico HumanitasOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03781869 | Study of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer | unknown | Phase 2 | 116 | Third Military Medical UniversityOTHER | 0 | Dec 20, 2018 | clinicaltrials |
| NCT03432156 | Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC) | unknown | Phase 2 | 68 | Beijing Friendship HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03776604 | PEG-rhG-CSF in Elderly Patients With Small Cell Lung Cancer Receiving Chemotherapy | unknown | N/A | 61 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03771404 | NSCLC Heterogeneity in Early Stage Patients and Prediction of Relapse Using a Personalized "Liquid Biopsy" | unknown | N/A | 50 | Hellenic Oncology Research GroupOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT03765775 | Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | unknown | Phase 2 | 20 | First Hospital of Shijiazhuang CityOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT03617029 | Localization for Deep Lung Nodules: Microcoil Versus Contrast Injection | unknown | N/A | 60 | National Taiwan University Hospital Hsin-Chu BranchOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT03732001 | A Study of Anlotinib in Combination With Docetaxel Versus Docetaxel Alone in Participants With Advanced NSCLC(ALTER-L024) | unknown | Phase 2 | 80 | China Medical University, ChinaOTHER | 1 | Nov 28, 2018 | clinicaltrials |
| NCT03754530 | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | unknown | Phase 2 | 162 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Nov 27, 2018 | clinicaltrials |
| NCT03750916 | Anlotinib Combined With Docetaxel for Advanced Non-squamous Non-Small Cell Lung Cancer(ACDFNSNSCLC) | unknown | Phase 2 | 46 | Qilu Hospital of Shandong UniversityOTHER | 0 | Nov 26, 2018 | clinicaltrials |
| NCT03751592 | Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer | unknown | Phase 1 / Phase 2 | 144 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., LtdINDUSTRY | 1 | Nov 26, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT03664843 | Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients | unknown | — | 120 | First Hospital of Shijiazhuang CityOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03735264 | Anlotinib Combined With Docetaxel for Advanced Non-Small Cell Lung Cancer（ALTER-L034）(ACDFNSCLC) | unknown | Phase 2 | 46 | The Affiliated Hospital of Qingdao UniversityOTHER | 0 | Nov 8, 2018 | clinicaltrials |
| NCT03732846 | Anlotinib in Treatment of Recurrent Small Cell Lung Cancer | unknown | Phase 2 | 43 | Peking University Cancer Hospital & InstituteOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT03728374 | Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma | unknown | Phase 2 | 38 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 0 | Nov 2, 2018 | clinicaltrials |
| NCT03725423 | Apatinib for Advanced Lung Squmamous Carcinoma | unknown | Phase 4 | 50 | Xuzhou Central HospitalOTHER | 0 | Oct 31, 2018 | clinicaltrials |
| NCT03723629 | Progression of Untreated Pulmonary Ground Glass Opacity | unknown | — | 2,000 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01788332 | Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)(PIN) | unknown | Phase 2 | 70 | Lisette NixonOTHER_GOV | 1 | Oct 26, 2018 | clinicaltrials |
| NCT03709953 | Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma(Spark-AL003) | unknown | Phase 2 | 33 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT03568799 | 4-[18F]Fluoroglutamine PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules(GLN) | unknown | N/A | 30 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 19, 2018 | clinicaltrials |
| NCT03710629 | A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver Genes | unknown | — | 750 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT03706703 | Rh-Endostatin (Endostar®) Continuous Intravenous Infusion | unknown | Phase 2 | 50 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03274349 | Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma | unknown | N/A | 150 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT03703596 | Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC | unknown | Phase 2 | 88 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT03700333 | Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLC | unknown | Phase 3 | 120 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03692442 | Evaluation of Efficacy and Toxicity of Nivolumab Monotherapy for Advanced Non-small Cell Lung Cancer After First-line Treatment Failure Based on Second-generation Sequencing and Liquid Chip Platform | unknown | — | 80 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03680183 | Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) | unknown | — | 300 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT03671538 | Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin | unknown | N/A | 62 | Lingyu LuoOTHER | 0 | Sep 17, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Feb 1, 2019source: clinicaltrials